PHILADELPHIA, PA, 21 December 2010 – ERT,
a global provider of technology and services to the pharmaceutical,
biotechnology and medical device industries, today confirmed that
the effective date of the previously announced retirement of Dr.
Michael J. McKelvey, its President and CEO, is December 21,
2010.
Dr. Joel Morganroth, currently ERT’s Chairman and Chief
Scientific Officer, has also been elected by the Board as President
and CEO until ERT hires a permanent CEO. Dr. Morganroth has
served as the Chairman of ERT’s Board of Directors since 1999
and as Chief Scientific Officer since April 2006. He previously
served as the company’s Chief Executive Officer from 1993 to
March 2001 and also has consulted for ERT since 1977. Dr.
Morganroth is also a globally recognized cardiologist and clinical
researcher and has had more than 10 years’ experience as a
medical review officer/expert for the U.S. Food and Drug
Administration (FDA).
Joel Morganroth
Dr. Morganroth commented, “We thank Dr. McKelvey for his
years of service and wish him well in his future
endeavors.”
“ERT is a leading provider of innovative solutions and is
well positioned for continued growth. In my expanded role, I will
continue to leverage my experience and knowledge of the
organization and domain expertise to strengthen our position in
clinical research associated with Cardiac Safety, Respiratory and
electronic Patient Reported Outcomes [ePRO]. With our superb
management team, we will continue our goal of enhanced growth
through the exciting development of adjacent markets.”
For further information on ERT and its technology and services
please email [email protected],
call +1 215 972 0420 or visit www.ert.com.
For further press information please contact Fiona Robinson, The
Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel,
Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539539, Fax +44
1477 539540, Email [email protected].
About ERT
Based in Philadelphia, PA, eResearchTechnology, Inc. (www.ert.com) is a global provider of
technology and services to the pharmaceutical, biotechnology and
medical device industries. The Company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG)
technology and services to evaluate cardiac safety in clinical
development. It is also a leading provider of centralized
respiratory technology and services to evaluate pulmonary function
efficacy and safety in clinical development. Sponsors can
further use the Company’s solutions to streamline the
clinical trials process by automating the collection, analysis, and
distribution of ePRO clinical data using multi-mode technology in
all phases of clinical development as well as selected medical
devices for the clinical trials and healthcare industries.
Statements included in this release may constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements involve a
number of risks and uncertainties, which could cause actual results
to differ materially from those expressed or implied from such
statements. These risks and uncertainties include, without
limitation, the Company’s ability to obtain new contracts,
variability in size, scope and duration of projects, integration of
acquisitions, competitive factors, technological development,
market demand, and other factors described in the Company’s filings
with the Securities and Exchange Commission. The Company undertakes
no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events, or
otherwise.
Media Contacts:
Fiona
Robinson
The Scott
Partnership
Tel: +44 1477
539539
John Blakeley
ERT
+1 215 972 0420
